BioPharma Resources

Company

Otsuka

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Otsuka Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc..

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

64

55 still marketed

Novel approvals

9

Approvals since 2021

9

Originals and new uses

Phase 3 trials

215

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (5)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • SEP-363856UlotarontPhase 37 trials

    Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder

  • JNT-517Phase 34 trials

    Otsuka · Phenylketonuria (PKU), Phenylketonuria

  • OPC-1085ELPhase 31 trial

    Otsuka · Open Angle Glaucoma or Ocular Hypertension

  • QuabodepistatOPC-167832, QBSPhase 31 trial

    Otsuka · Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis

  • VIS954Phase 22 trials

    Otsuka · Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Inflammatory Skin Diseases

Recruiting Phase 3 trials

Largest first.

Marketed drugs (55)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.